These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37034363)

  • 1. The Anxiety and Depression in Rheumatoid Arthritis Patients Treating with Disease-Modifying Anti-Rheumatic Drugs during the COVID-19 Pandemic.
    Sargın G; Baygin H; Senturk T
    Mediterr J Rheumatol; 2022 Dec; 33(4):430-436. PubMed ID: 37034363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
    Ding Q; Shiltz D; Hossami D; Konieczny AM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.
    Migkos MP; Kaltsonoudis E; Pelechas E; Drossou V; Karagianni PG; Kavvadias A; Voulgari PV; Drosos AA
    Rheumatol Int; 2021 May; 41(5):903-909. PubMed ID: 33655421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy.
    Intongkam S; Samakarnthai P; Pakchotanon R; Narongroeknawin P; Assavatanabodee P; Chaiamnuay S
    J Clin Rheumatol; 2019 Dec; 25(8):329-334. PubMed ID: 31764493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the correlation between mood disorder symptoms and disease activity and functional status in rheumatoid arthritis patients.
    Pamukcu M; İzci Duran T; Ulusoy H; Altınbaş K
    Turk J Med Sci; 2021 Dec; 51(6):3008-3016. PubMed ID: 34773692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying anti-rheumatic drugs after an average of 11.4-year follow-up.
    Ren Y; Yang Q; Luo T; Lin J; Jin J; Qian W; Weng X; Feng B
    J Orthop Surg Res; 2021 Jan; 16(1):84. PubMed ID: 33504345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic pain and depression in patients with rheumatoid arthritis: results of five - year follow - up].
    Lisitsyna TA; Abramkin AA; Veltishchev DY; Seravina OF; Kovalevskaya OB; Zeltyn AE; Glukhova SI; Nasonov EL; Krasnov VN
    Ter Arkh; 2019 May; 91(5):8-18. PubMed ID: 32598671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes in Puerto Ricans with Rheumatoid Arthritis (RA) Receiving Early Treatment with Disease-Modifying Anti-Rheumatic Drugs using the American College of Rheumatology Definition of Early RA.
    Varela-Rosario N; Arroyo-Ávila M; Fred-Jiménez RM; Díaz-Correa LM; Pérez-Ríos N; Rodríguez N; Ríos G; Vilá LM
    Open Rheumatol J; 2017; 11():136-144. PubMed ID: 29387286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
    Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
    Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of yoga based mind-body intervention on systemic inflammatory markers and co-morbid depression in active Rheumatoid arthritis patients: A randomized controlled trial.
    Gautam S; Tolahunase M; Kumar U; Dada R
    Restor Neurol Neurosci; 2019; 37(1):41-59. PubMed ID: 30714983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases.
    Lisitsyna TA; Veltishchev DY; Seravina OF; Kovalevskaya OB; Starovoytova MN; Desinova OV; Abramkin AA; Ovcharov PS; Vasil'ev VI; Alekberova ZS; Krasnov VN; Nasonov EL
    Ter Arkh; 2018 May; 90(5):30-37. PubMed ID: 30701894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the Disease Characteristics and the Treatment on Psychological Status in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Esen SA; Karabulut Y; Esen I; Atmis V
    Curr Rheumatol Rev; 2018; 14(3):271-278. PubMed ID: 28758586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.
    Sahebari M; Mirfeizi Z; Hashemzadeh K; Salavati Nik E; Gholampoor Shamkani N
    Arch Bone Jt Surg; 2022 Nov; 10(11):964-968. PubMed ID: 36561225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Socioeconomic and therapy factor influence on self-reported fatigue, anxiety and depression in rheumatoid arthritis patients.
    Lapčević M; Vuković M; Gvozdenović BS; Mioljević V; Marjanović S
    Rev Bras Reumatol Engl Ed; 2017; 57(6):545-556. PubMed ID: 29173692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study.
    Michaud K; Pedro S; Wipfler K; Agarwal E; Katz P
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1322-1331. PubMed ID: 33787086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.